Ferozsons Laboratories Limited was incorporated as a private limited company on 28 January 1954 and was converted into a public limited company on 08 September 1960. The Company is primarily engaged in the imports, manufacture and sale of pharmaceutical products and medical devices.
Where the price sits against its own year, and how it has traded since the opening bell.
Today's price sits 31% of the way up its 52-week range
Bounds are the highest and lowest daily close of the past year. PSX does not publish an intraday high or low in its end-of-day feed, so a spike within a session is not counted.
The signals a trader reads off today's board, with the fundamentals that qualify them.
Buyers are stronger
How much money is this company making, and is it growing?
Quick parameters that help you judge whether a stock is rewarding shareholders and growing.
Cash paid out over the last twelve months, against today's price. A high yield is attractive for income — check the payout is covered by earnings before relying on it.
trailing 12m DPS ÷ price × 100The share of profit handed back as dividends. Above 100% means the company paid out more than it earned that year, which cannot continue indefinitely.
DPS ÷ EPS × 100Does this company share its profits with shareholders, and how reliably?
| Announced | Dividend | DPS | Book closure |
|---|---|---|---|
| 2025-09-23 | 40% of face value · final | Rs 4 | 2025-10-18 → 2025-10-25 |
What the price has been doing lately, read off its own history. These describe where a reading sits — never what to do about it.
The price line is close-only and unadjusted. PSX's end-of-day feed carries no intraday high or low, and a bonus issue or split leaves a step in the series that is not a fall.
A blank figure means not known, never zero. Ratios are computed by PSX Lens from the exchange's published statements, not published by the exchange itself.
The price (Rs 348.00) is above today's open (Rs 347.00) — buyers pushed it up.
PSX halts a scrip that moves more than 10% from its last close. Today that band runs from Rs 312.42 to Rs 381.84.
Balance-sheet lines — total assets, equity, liabilities, and the book value and return-on-equity figures built from them — come from the audited filing PDFs and are not yet extracted. They are omitted here rather than shown as zero.
Rupees paid per rupee of annual earnings. The sector median is 15.48×.
price ÷ earnings per shareThe same ratio against average earnings rather than the latest year. For a cyclical company this is the fairer comparison — a trailing P/E on peak profits flatters it.
price ÷ normalized EPSCompound annual growth of the share price alone, excluding dividends. It says how the price has rewarded a long-term holder, not what it will do next.
(latest ÷ earliest) ^ (1 ÷ years) − 1How fast the payout itself has grown. Sustained growth depends on earnings growing too — read it beside the payout ratio.
(latest yr DPS ÷ earliest yr DPS) ^ (1 ÷ years) − 1| 305.87 |
| 11.21 |
| GSKCH | GlaxoSmithKline Consumer Healthcare | — | — |
Sector median P/E 15.48× across 18 companies · FEROZ sits +52.20% against it
Levels
Pivot levels · from the last session
Moving averages
| MA | Value | Price vs | Side |
|---|---|---|---|
| SMA 5 | 357.80 | -2.74% | below |
| SMA 10 | 356.70 | -2.44% | below |
| SMA 15 | 356.53 | -2.39% | below |
| SMA 20 | 360.47 | -3.46% | below |
| SMA 30 | 368.21 | -5.49% | below |
| SMA 50 | 377.53 | -7.82% | below |
| SMA 100 | 383.28 | -9.21% | below |
| SMA 150 | 380.92 | -8.64% | below |
| SMA 200 | 384.67 | -9.53% | below |
| EMA 9 | 356.38 | -2.35% | below |
| EMA 12 | 357.68 | -2.71% | below |
| EMA 20 | 361.47 | -3.73% | below |
| EMA 26 | 364.18 | -4.44% | below |
| EMA 50 | 371.55 | -6.34% | below |
| EMA 200 | 383.44 | -9.24% | below |
| VWMA 20 | 362.52 | -4.01% | below |
Oscillators
Volatility & volume
Computed from delayed daily bars, never live. 311 of 320 sessions have their high and low stood in for by the open and close, because the PSX end-of-day feed omits them — anything built on a true daily range is approximate here.